Medulloblastoma: from myth to molecular
V Ramaswamy, MD Taylor - Journal of Clinical Oncology, 2017 - ascopubs.org
Current therapies for medulloblastoma were introduced primarily in the 1980s and consist of
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …
Medulloblastoma: From Myth to Molecular
V Ramaswamy, MD Taylor - Journal of Clinical Oncology, 2017 - cir.nii.ac.jp
抄録< jats: p> Current therapies for medulloblastoma were introduced primarily in the 1980s
and consist of predominantly cytotoxic, nontargeted approaches. Mortality from …
and consist of predominantly cytotoxic, nontargeted approaches. Mortality from …
Medulloblastoma: From Myth to Molecular
V Ramaswamy, MD Taylor - Journal of clinical oncology …, 2017 - pubmed.ncbi.nlm.nih.gov
Current therapies for medulloblastoma were introduced primarily in the 1980s and consist of
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …
Medulloblastoma: From Myth to Molecular.
V Ramaswamy, MD Taylor - … of Clinical Oncology: Official Journal of …, 2017 - europepmc.org
Current therapies for medulloblastoma were introduced primarily in the 1980s and consist of
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …
[PDF][PDF] Medulloblastoma: From Myth to Molecular
V Ramaswamy, MD Taylor - 2017 - scholar.archive.org
Current therapies for medulloblastoma were introduced primarily in the 1980s and consist of
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …